[Federal Register Volume 86, Number 210 (Wednesday, November 3, 2021)]
[Notices]
[Page 60653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23982]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-921]
Bulk Manufacturer of Controlled Substances Application: Nanosyn
Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Nanosyn Inc. has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before January 3, 2022.
Such persons may also file a written request for a hearing on the
application on or before January 3, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on September 23, 2021, Nanosyn Inc., 3331 Industrial
Drive, Suite B, Santa Rosa, California 95403-2062, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Oxymorphone............................ 9652 II
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company is a contract manufacturer. At the request of the
company's customers, it manufactures derivatives of the above
controlled substances in bulk form. No other activities for these drug
codes are authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-23982 Filed 11-2-21; 8:45 am]
BILLING CODE P